Baselga, José <br/><br/>
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Mar 2010 
 - 1138-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.24.2024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--chemistry<br/>Disease Progression<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Receptor, ErbB-2--analysis<br/>Stroke Volume--drug effects<br/>Trastuzumab<br/>Ventricular Function, Left--drug effects